Nose-to-Brain Delivery of Cancer-Targeting Paclitaxel-Loaded Nanoparticles Potentiates Antitumor Effects in Malignant Glioblastoma.
Irfan UllahKunho ChungSumin BaeYan LiChunggu KimBoyoung ChoiHye Yeong NamSun Hwa KimChae-Ok YunKuen-Yong LeePriti KumarSang-Kyung LeePublished in: Molecular pharmaceutics (2020)
Glioblastoma multiforme (GBM) is an aggressive tumor with no curative treatment. The tumor recurrence after resection often requires chemotherapy or radiation to delay the infiltration of tumor remnants. Intracerebral chemotherapies are preferentially being used to prevent tumor regrowth, but treatments remain unsuccessful because of the poor drug distribution in the brain. In this study, we investigated the therapeutic efficacy of cancer-targeting arginyl-glycyl-aspartic tripeptide (RGD) conjugated paclitaxel (PTX)-loaded nanoparticles (NPs) against GBM by nose-to-brain delivery. Our results demonstrated that RGD-modified PTX-loaded NPs showed cancer-specific delivery and enhanced anticancer effects in vivo. The intranasal (IN) inoculation of RGD-PTX-loaded NPs effectively controls the tumor burden (75 ± 12% reduction) by inducing apoptosis and/or inhibiting cancer cell proliferation without affecting the G0 stage of normal brain cells. Our data provide therapeutic evidence supporting the use of intranasally delivered cancer-targeted PTX-loaded NPs for GBM therapy.
Keyphrases
- papillary thyroid
- cancer therapy
- drug delivery
- squamous cell
- cell proliferation
- white matter
- emergency department
- resting state
- lymph node metastasis
- oxidative stress
- signaling pathway
- stem cells
- photodynamic therapy
- machine learning
- squamous cell carcinoma
- childhood cancer
- induced apoptosis
- multiple sclerosis
- young adults
- prognostic factors
- risk factors
- big data
- drug induced
- radiation induced
- artificial intelligence
- locally advanced
- cell therapy
- smoking cessation